sultamicillin (ampicillin-sulbactam)

contains ampicillin & sulbactam

Also Known As:

ampicillin-sulbactam; Unasyn; CP 49,952; CP 49952; Combisid; 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-((aminophenylacetyl)amino)-3,3-dimethyl-7-oxo-, (((3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)hept-2-yl)carbonyl)oxy)methyl ester, S,S-dioxide, (2S-(2alpha(2R*,5S*),5alpha,6beta(S*)))-

Networked: 482 relevant articles (80 outcomes, 89 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Lode, H: 4 articles (02/2008 - 09/2001)
2.	Allewelt, M: 3 articles (02/2008 - 10/2001)
3.	Izumi, Shinyu: 2 articles (10/2022 - 09/2011)
4.	Sugiyama, Haruhito: 2 articles (10/2022 - 09/2011)
5.	Suzuki, Manabu: 2 articles (10/2022 - 09/2011)
6.	Takeda, Yuichiro: 2 articles (10/2022 - 09/2011)
7.	Shields, Ryan K: 2 articles (12/2021 - 05/2015)
8.	Buller, Johannes: 2 articles (02/2021 - 08/2016)
9.	Kreppel, Matthias: 2 articles (02/2021 - 08/2016)
10.	Zirk, Matthias: 2 articles (02/2021 - 08/2016)

Related Diseases

1.	Infections 03/01/1993 - "We think that ampicillin/sulbactam combination is very effective in prevention and treatment of shunt infections." 04/01/1989 - "Sultamicillin has been shown to be clinically effective in non-comparative trials in patients with infections of the respiratory tract, ears, nose and throat, urinary tract, skin and soft tissues, as well as in obstetric and gynaecological infections, and in the treatment of gonorrhoea. " 01/01/2002 - "Ampicillin/sulbactam has also proved effective in the prevention of post-operative surgical infections in pediatric patients. " 09/01/2001 - "The fractional inhibitory concentration indices were between 0.19 and 0.56 in combination with 6.25 and 25 mg/L EGCg, respectively, indicating that ampicillin/sulbactam and EGCg combination may be effective against MRSA infections." 06/01/1999 - "Ampicillin-sulbactam provides effective coverage for patients with the above infections and is as effective as the broader-spectrum agent."
2.	Respiratory Tract Infections (Respiratory Tract Infection) 01/01/1992 - "An open non-comparative pilot study of the safety and efficacy of oral sultamicillin in the treatment of mild to moderate upper respiratory tract infections in children." 01/01/1992 - "Treatment of lower respiratory tract infections with sultamicillin." 11/01/1991 - "Ampicillin/sulbactam in lower respiratory tract infections: a review." 02/01/1991 - "[Clinical evaluation of sultamicillin in lower respiratory tract infections]." 01/01/1989 - "[Activity of an ampicillin/sulbactam combination in respiratory infections]."
3.	Endocarditis 05/18/2021 - "With a suspicion of infective endocarditis, we started administering intravenous ampicillin/sulbactam. " 03/01/2023 - "We selected ampicillin-sulbactam to treat infective endocarditis based on a sensitivity examination, and the patient's post-operative clinical course was uneventful. " 10/01/1999 - "Treatment of experimental staphylococcal endocarditis due to a strain with reduced susceptibility in vitro to vancomycin: efficacy of ampicillin-sulbactam." 06/01/2023 - "Although multiple blood cultures were negative, ampicillin/sulbactam and ceftriaxone were initially administered because of suspected blood culture-negative endocarditis. " 04/01/1995 - "Ampicillin, sulbactam, and rifampin combination treatment of experimental methicillin-resistant Staphylococcus aureus endocarditis in rabbits."
4.	Soft Tissue Infections 01/01/1991 - "Ampicillin-sulbactam may be used for treatment of intraabdominal, gynecologic, urinary tract, and skin and soft tissue infections." 04/01/1987 - "Sultamicillin in the treatment of superficial skin and soft tissue infections in children." 08/01/2000 - "Ampicillin/sulbactam and cefoxitin were equally effective for the empirical treatment of cutaneous or other soft-tissue infections in injection drug abusers and patients who did not inject drugs." 04/01/1987 - "Fifty-two children with superficial skin and soft tissue infections were randomized to receive sultamicillin or cloxacillin for 7 days. " 08/01/2000 - "A randomized, double-blind trial compared the clinical and bacteriologic efficacy of ampicillin/sulbactam (2 g/1 g) and cefoxitin (2 g) administered intravenously every 6 h to patients with (n=49) or without (n=47) histories of injection drug abuse who presented with cutaneous or other soft-tissue infections. "
5.	Pneumonia (Pneumonitis) 02/02/2023 - "This study aimed to assess the dosing regimens of ampicillin/sulbactam for pneumonia based on pulmonary pharmacokinetic (PK)/pharmacodynamic (PD) target attainment. " 01/01/2021 - "This study sought to investigate whether dosing frequency (the number of doses per day) affects the antimicrobial efficacy and safety of ampicillin/sulbactam (ABPC/SBT) in Japanese elderly pneumonia patients treated with ABPC/SBT at 6 g/day. " 02/01/2014 - "The aim of this study was to assess the influence of age on the steady-state pharmacokinetics and pharmacokinetic/pharmacodynamic parameters of ampicillin/sulbactam in the population of elderly patients (age ≥65 years) with community-acquired pneumonia (CAP). " 02/02/2023 - "These findings should facilitate the selection of ampicillin/sulbactam regimens for pneumonia caused by various bacteria, including A. " 02/02/2023 - "Pulmonary Pharmacokinetic and Pharmacodynamic Evaluation of Ampicillin/Sulbactam Regimens for Pneumonia Caused by Various Bacteria, including Acinetobacter baumannii."

Related Drugs and Biologics

1.	Ampicillin (Omnipen)
2.	sultamicillin (ampicillin-sulbactam)
3.	Anti-Bacterial Agents (Antibiotics)
4.	Colistin (Coly-Mycin)
5.	Sulbactam
6.	Vancomycin
7.	beta-Lactamases (beta-Lactamase)
8.	Clindamycin (Cleocin)
9.	Cefoxitin (Cefoxitin Sodium)
10.	Clavulanic Acid (Potassium Clavulanate)

Related Therapies and Procedures

1.	Therapeutics
2.	Aftercare (After-Treatment)
3.	Cholecystectomy
4.	Cesarean Section (Caesarean Section)
5.	Free Tissue Flaps